Edwards Lifesciences (EW) is back in focus after new data showed its PASCAL tricuspid repair system outperformed medical therapy in the CLASP II TR trial, with benefits sustained through one year. Recent data and regulatory milestones have come alongside clear momentum in the Edwards Lifesciences share price, with a 1-month share price return of 11.79% and a 1-year total shareholder return of 13.12% on a closing share price of US$95.19 as of 4 November 2026. This suggests investors are...
Edwards Lifesciences (NYSE:EW) highlighted new clinical data for its transcatheter tricuspid repair and transcatheter aortic valve replacement programs, including results from the CLASP IITR trial of the PASCAL system and the PROGRESS trial evaluating TAVR in certain patients with moderate aortic st
Edwards Lifesciences earns a buy on FDA approvals, cardiology niche strength, and solid cash flow. Read here for a detailed analysis of EW stock.
Detailed price information for Incyte Corp (INCY-Q) from The Globe and Mail including charting and trades.
Edwards Lifesciences recalls Commander M delivery systems following balloon burst reports and 1 death. Read the FDA alert.
The U.S. Food and Drug Administration (FDA) issued a high-risk early alert after Edwards Lifesciences Corp. (NYSE:EW) recalled specific lots of its Commander M delivery systems due to reports of balloons bursting during procedures, resulting in one death and a serious injury. Recall Of Commander M Delivery Systems The delivery systems help implant a replacement mitral heart valve through blood vessels, bypassing the need for open-chest surgery. However, the company received three distinct report
This is the newest page. Registered accounts read further back.